Perineural invasion (PNI) is one of the established prognostic factors in pancreatic ductal adenocarcinoma (PDAC). However, the prognostic significance of PNI in patients with PDAC who received neoadjuvant therapy and pancreaticoduodenectomy is not clear. In this study, we performed a detailed examination of neural invasion in pancreaticoduodenectomy specimens from 212 patients with PDAC who received neoadjuvant chemoradiation (treated group) and in 60 untreated patients at our institution between January 1999 and December 2007. The frequency of PNI was higher in the untreated group (80%, 48/60) than in the treated group (58%, 123/212). For the 123 treated cases that were positive for PNI, extratumoral PNI, intratumoral PNI, intrapancreatic PNI only, extrapancreatic PNI, and intraneural invasion were identified in 86 (69.9%), 37 (30.1%), 11 (8.9%), 112 (91.1%), and 35 cases (28.5%), respectively. The presence of PNI correlated with tumor size, margin status, lymph node metastasis, pathologic tumor, and American Joint Committee on Cancer stages in the treated group. Tumor involvement of nerves >0.8 mm correlated with higher frequency of positive margin compared with tumors with PNI involving nerves r0.8 mm but not with other clinicopathologic parameters and survival. In the treated group, the presence of PNI or intraneural invasion correlated significantly with shorter disease-free survival and overall survival compared with no PNI or PNI only, respectively. PNI was an independent prognostic factor for both disease-free survival and overall survival in multivariate analysis. Our results showed that PNI plays an important role in the progression of PDAC and in predicting prognosis in this group of patients. FIGURE 2. Kaplan-Meier survival curves of DFS (A and C) and OS (B and D) stratified by the absence or presence of PNI (A and B) or intraneural invasion (C and D) in patients with PDAC who received neoadjuvant therapy and PD. The patients with PNI or intraneural invasion have shorter DFS and OS compared with patients who have no PNI. Only data from the treated group are shown.
P ancreatic ductal adenocarcinoma (PDAC) is a malignancy with a very poor prognosis. A vast majority of patients with PDAC present with surgically unresectable disease at the time of diagnosis because of locoregional spread or metastatic dissemination. 9, 12 In patients with potentially resectable disease, subclinical metastases are often present at the time of diagnosis and surgery, which are undetected by imaging. Therefore, disease recurrence after a potentially curative pancreatectomy is common, and the long-term survival rate for patients who have undergone pancreatectomy is only 10% to 20%. 11, 25 Adjuvant treatment in the form of combined chemoradiation therapy is a standard form of treatment option for PDAC and has been shown to improve the 5-year survival and to delay the time to tumor recurrence in patients who have undergone pancreatectomy. 20, 22, 23 However, the overall survival (OS) for patients with PDAC has not changed significantly over the last 4 decades, despite significant improvements in operative techniques and advance in medical oncology. 8 Recently, several tertiary referral centers worldwide, including our institution, have demonstrated the safety and feasibility of preoperative neoadjuvant chemoradiation for PDAC. 7, 15, 18, 26, 27 Evans et al 7 reported a median survival of 34 months and 36% 5-year survival rate for the 64 patients who underwent pancreaticoduodenectomy (PD) compared with a median survival of 7 months and 0% 5-year survival for the 22 patients who did not undergo PD in a phase II trial of neoadjuvant gemcitabine-based chemoradiation in patients with PDAC. In another phase II trial of 90 patients who received preoperative gemcitabine and cisplatin chemotherapy in addition to gemcitabine-based chemoradiation, Varadhachary et al 27 reported a median survival of 31 months for the 52 patients who underwent PD compared with a median survival of 10.5 months for the 27 patients who did not undergo surgical resection. These data suggest that neoadjuvant chemoradiation may identify patients with a favorable tumor biology who would likely benefit the most from surgery, thereby maximizing rates of postoperative survival.
Little is known about the prognostic factors for survival in patients with PDAC who receive neoadjuvant chemoradiation and PD. Recently, we showed that posttherapy pathologic stage, lymph node status, and the number of positive regional lymph nodes are independent prognostic factors in this group of patients. 6 PDAC characteristically spreads by infiltration of lymphatics, blood vessels, and nerves. Perineural invasion (PNI) has been reported in 70.8% to 93% of the PD specimens resected for PDAC and has been shown to be associated with peritoneal dissemination and worse survival in patients with PDAC who underwent PD. 1, 2, 4, 16 However, the prevalence of PNI and its prognostic significance in patients with PDAC who received neoadjuvant chemoradiation therapy and subsequent PD is not clear. In this study, we performed detailed histologic evaluation of PNI, intraneural invasion, the size of the nerve involved by the tumor, and the location of neural invasion in 212 patients who received neoadjuvant chemoradiation therapy and PD. The results were correlated with survival and other clinical and pathologic parameters. Our data showed that the presence of PNI and intraneural invasion is an important prognostic factor in this group of patients.
MATERIALS AND METHODS

Patient Population
Our study population consisted of 212 patients with a histologically confirmed diagnosis of PDAC who received neoadjuvant chemoradiation therapy and subsequently underwent PD at our institution from January 1999 to December 2007. There were 124 male and 88 female patients with ages ranging from 39 to 85 years (median age, 63 y). Thirty-nine patients (18.4%) received neoadjuvant fluoropyrimidine-based chemoradiation (group 1), 66 (31.1%) received neoadjuvant gemcitabine-based chemoradiation (group 2), 70 (33.0%) received systemic chemotherapy followed by gemcitabine-based chemoradiation (group 3), 32 (15.1%) received systemic chemotherapy followed by fluoropyrimidine-based chemoradiation (group 4), and the remaining 5 (2.4%) patients received neoadjuvant systemic chemotherapy alone (group 5). Of these patients, 136 patients (64.2%) (groups 2 and 3) were treated on the basis of previously published protocols. 7, 27 All patients underwent restaging evaluation after completion of neoadjuvant therapy. PD was performed only in patients with resectable disease without disease progression or metastasis and who had no contraindications to major abdominal surgery. Patients who underwent distal pan-createctomy for PDAC and those who underwent PD for other types of pancreatic tumors were excluded. Sixty consecutive patients who did not receive any form of neoadjuvant therapy before PD (the untreated group) during the same time period at our institution were used as the control group. There were 27 female and 33 male patients with ages ranging from 24.9 to 80.9 years (median age, 60.9 y) in our untreated group. Among these 60 untreated patients, 2 had stage I disease, 13 had stage IIA disease, and 45 had stage IIB disease. The study was approved by the Institutional Review Board of the University of Texas M.D. Anderson Cancer Center.
Patient clinical and follow-up information through December 2009 was extracted from a prospectively maintained database. The clinical and follow-up data from all patients have been verified by an independent review of patient medical records and by the US Social Security Index. Local/regional or distant recurrence at first site or sites was classified on the basis of a computed tomography scan, and biopsy confirmation of metastasis was rarely performed. Local/regional recurrence was defined as recurrence in the region of the pancreatic bed or at the root of the mesentery, soft tissues, or lymph nodes adjacent to the pancreatic bed. Distant metastasis was defined as radiographic evidence of tumor spread to the liver, lungs, peritoneal cavity (including ascites), or other distant organs.
Pathologic Examination
The histopathologic assessment of PNI and other pathologic parameters was carried out by reviewing the archival hematoxylin and eosin-stained slides in all the cases. The total number of slides reviewed from the pancreas and tumor ranged from 3 to 45 (the mean number of slides, 14). The cases were examined for the presence or absence of PNI, which was defined as the presence of viable tumor cells in the perineural space. The presence of acellular mucin in the perineural space with no viable tumor cells was considered as negative for PNI in this study. When PNI was present, the location of PNI was further classified as intrapancreatic (defined as PNI with at least 2 sides surrounded by benign pancreatic tissue) or extrapancreatic [defined as PNI in soft tissue with no surrounding benign pancreatic tissue (islet of Langerhans, pancreatic acini, or benign pancreatic ductules)] and as intratumoral (PNI present within the main tumor mass) or extratumoral (PNI present outside the main tumor mass) ( Fig. 1 ).
Patients who had both intrapancreatic and extrapancreatic invasion were classified as having extrapancreatic invasion, and those who had both intratumoral and extratumoral invasion were classified as having extratumoral invasion. The presence of intraneural invasion was defined by histology as the presence of PNI with tumor cells invading into and/or with irregular destruction of the axon of the nerve bundle(s) as reported previously. 19 The maximum diameter of the nerves involved by tumor was measured microscopically and recorded in each case. In addition, the tumor size, differentiation, lymph node status, and margin status were also reviewed and recorded. If any of the PD margins was involved by PDAC, the case was classified as margin positive. The posttherapy pathologic staging was grouped according to the American Joint Committee on Cancer (AJCC) Staging Manual, 7th edition. 5 
Statistical Analysis
Statistical analyses were performed using Statistical Package for Social Sciences software (for Windows 12.0, SPSS Inc., Chicago, IL). The w 2 analysis was used to compare categorical data, and analysis of variance was 
RESULTS
Correlation of Nerve Invasion With Clinicopathologic Parameters in Patients Who Received Neoadjuvant Therapy
Among the 212 patients, PNI was identified in 123 (58%) patients. For the 123 cases that were positive for PNI, extratumoral PNI, intratumoral PNI, intrapancreatic PNI only, extrapancreatic PNI, and intraneural invasion were identified in 86 (69.9%), 37 (30.1%), 11 (8.9%), 112 (91.1%), and 35 (28.5%) cases, respectively. The size of the involved nerves ranged from 0.1 to 4.0 mm with a median size of 0.8 mm and an average of 1.2 mm.
The correlation of PNI with clinicopathologic features is shown in Table 1 . The presence of PNI correlated significantly with posttherapy tumor size (P = 0.03), resection margin status (P = 0.03), posttherapy pathologic tumor stage (ypT, P = 0.001), lymph node status (P = 0.005), and posttherapy AJCC stage (P<0.001). During follow-up, 78.1% (96/123) patients with PNI developed local recurrence or distant metastasis compared with 60.7% (54/89) of patients who had no PNI (P = 0.02). There was no significant correlation of PNI with age, sex, tumor differentiation, or different neoadjuvant treatment regimens (Table 1) . Among the 123 cases with PNI, the presence of intraneural invasion correlated with higher frequency of local/distant recurrence compared with those cases with PNI only. Local/distant recurrence was observed in 94.3% (33/35) of cases with intraneural invasion compared with 71.6% (63/ 88) of cases with PNI only (P<0.01). However, no significant correlation between intraneural invasion and other clinicopathologic parameters was observed. Using the median size (0.8 mm) of the involved nerves as cutoff, a positive resection margin was observed in 15 of 58 (25.9%) cases that had PNI involving nerves of >0.8 mm compared with 4/65 (6.2%) cases that had PNI involving nerves of r0.8 mm (P = 0.005). However, we did not observe significant correlation of the size of the involved nerves with other clinicopathologic parameters (P>0.05, data not shown). No significant difference in any of the above-mentioned clinicopathologic parameters was observed between the group with intratumoral PNI only and the group with extratumoral PNI or between the group with intrapancreatic PNI only and the group with extrapancreatic PNI (Fisher exact tests, P>0.05, data not shown).
Correlation of Nerve Invasion With Survival in Patients Who Received Neoadjuvant Therapy
The median follow-up of all patients was 29.5 months, ranging from 7.6 to 122.3 months. Patients without PNI had a median DFS of 22.0 months [95% confidence interval (CI), 14.7-29.4 mo], which was significantly longer than the 11.0 months (95% CI, 8.9-13.1 mo) for patients with PNI (P = 0.002, Fig. 2A ). Patients with PNI also had shorter OS than those without PNI. The median OS for patients without PNI was 56.1 months (95% CI, 36.7-75.6 mo) compared with 28.5 Fig. 3 ). There is also no difference in DFS or OS between the group of patients with PNI involving nerves of r0.8 mm and the group of patients with PNI involving nerves of >0.8 mm (P>0.05, data not shown).
The results from univariate Cox regression analysis for DFS and OS are shown in Table 2 . Both DFS and OS were significantly associated with positive lymph node status, posttherapy AJCC tumor stage, and PNI (P<0.05). The resection margin status and ypT correlated significantly with OS (P<0.05) but not with DFS. There was no significant association of either DFS or OS with sex, intraoperative blood loss, tumor differentiation, or tumor size (P>0.05, Table 2 ). In multivariate analysis, the presence of PNI was an independent prognostic factor for both OS and DFS (P<0.05). Lymph node status and resection margin status were also independent prognostic factors for OS but not for DFS (Table 3 ).
Nerve Invasion in Patients Who Did Not Receive Neoadjuvant Therapy
To compare the frequency of nerve invasion and to evaluate the role of PNI in predicting the prognosis in patients with PDAC who did not receive neoadjuvant therapy, we examined PNI and its correlation with survival and clinicopathologic features in 60 consecutive untreated patients during the same time period at our institution. We found that PNI was present in 80% (48/60) of untreated cases, which was higher than those who received neoadjuvant therapy (58%, P = 0.002). Similar to our findings in patients who had received neoadjuvant therapy, the presence of PNI correlated with lymph node metastasis and AJCC stage in the untreated group. Lymph node metastasis was present in 83% (40/ 48) of untreated patients who had PNI compared with 42% (5/12) of those who lacked PNI (P = 0.006). Local recurrence was observed in 31% (15/48) of untreated patients who had PNI compared with 0% (0/12) of those who lacked PNI (P = 0.03). However, we did not observe significant correlations of PNI with other clinicopathologic parameters, distant metastasis, DFS, or OS in the untreated group (P>0.05; data not shown).
DISCUSSION
In this study, we examined nerve invasion in the PD specimens from 212 patients with PDAC who had received neoadjuvant therapy. We found that the presence of PNI correlated with tumor size, resection margin status, posttherapy tumor (ypT) stage, lymph node status, and posttherapy AJCC stage. We also showed that the presence of PNI and intraneural invasion correlated with both DFS and OS. The presence of PNI was an independent prognostic factor for both DFS and OS. Therefore, perineural and intraneural invasion play an important role in tumor progression and prognosis in patients with PDAC who have received neoadjuvant therapy and PD.
Neoadjuvant therapy has been increasingly used in patients with PDAC as an alternative to the conventional approach, which is to perform pancreatectomy first followed by adjuvant therapy. 7, 27 Several studies, including 2 large phase II trials from our institution, have reported median survival durations of up to 34 months and up to 36% 5-year survival rate in patients with potentially resectable PDAC who were treated with neoadjuvant chemoradiation followed by PD. 7, 26, 27 At our institution, a multidisciplinary approach has been used to develop clinical trials exploring the use of protocol-based neoadjuvant therapy before surgical resection. From 1990 to 2002, the numbers of patients who underwent PD, distal, or total pancreatectomy at our institution were 302 (92%), 20 (6%), or 7 (2%), respectively. Among these patients, 253 (84%) received neoadjuvant therapy. 14 In our previous study, we showed that posttherapy pathologic AJCC stage and number of positive lymph nodes are independent prognostic factors in patients with PDAC who have received neoadjuvant therapy and PD. 6 However, a detailed study of other histopathologic factors in PD specimens after neoadjuvant chemoradiation is lacking.
PNI is an important pathway by which tumors progress and spread to adjacent tissue or organs and has been shown to be an important prognostic factor in many types of human malignancies. In patients with PDAC who underwent PD first, but received no preoperative neoadjuvant therapy, PNI was frequently identified in PD specimens, with reported frequencies ranging from 70.8% to 93.0%. 1, 2, 4, 16 In this study, we found that PNI was present in 80% of untreated patients, which was significantly higher than the 58% in the 212 patients with PDAC who received neoadjuvant therapy and PD. Consistent with our data, Barbier et al 2 showed that PNI was present in 43% of the PD specimens from patients with PDAC who received neoadjuvant therapy, which is significantly lower than the 93% in those patients who received surgery first in their study. The presence of PNI has been shown to be associated with peritoneal dissemination and worse survival in patients who received surgery first but no neoadjuvant therapy. 1, 4, 16 The prognostic value of PNI is, however, not clear in patients with PDAC who received neoadjuvant therapy and subsequent PD. Our data showed that PNI correlated with larger tumor size, higher rate of positive resection margin, posttherapy tumor (ypT) stage, higher rate of lymph node metastasis, and posttherapy AJCC stage in patients with PDAC who received neoadjuvant therapy. Using multivariate analysis, we demonstrated that the presence of PNI was an independent prognostic factor for both DFS and OS in our patient population. In addition, our data also showed that the presence of intraneural invasion correlated with poor DFS and OS compared with those patients with PNI only. Similar to our results, the presence of PNI has been shown to be associated with posttherapy pathologic stage and a worse 5-year survival rate in patients with locally advanced gastric cancer who received neoadjuvant therapy. 13 In a cohort of 297 patients with locally advanced rectal adenocarcinoma who received neoadjuvant therapy, Guillem et al 10 showed that the presence of PNI, along with lymphovascular invasion, tumor response >95%, and lymph node metastasis, is an independent prognostic factor for both DFS and OS in their patient population. Together, these results support the notion that PNI plays an important role in tumor progression and prognosis in patients who have received neoadjuvant therapy.
Consistent with our findings in the patients who received neoadjuvant therapy, we found that the presence of PNI was associated with higher frequency of lymph node metastasis and local recurrence in our untreated patient population. In contrast to the previous reports that have shown that PNI is associated with peritoneal dissemination and worse survival in patients who received surgery first but no neoadjuvant therapy, 1, 4, 16 we did not observe any significant correlation of PNI with other clinicopathologic parameters, distant metastasis, DFS, or OS in our untreated group. However, our untreated group is small compared with other studies. The difference in the prognostic significance of PNI between the untreated group and those patients who received neo-adjuvant therapy in this study may be partly because of the highly selective patient population for PD who received neoadjuvant therapy in our treated group to the exclusion of those patients whose tumor had more aggressive clinical behavior during the neoadjuvant chemoradiation treatment.
Previous studies have shown that the nerve diameter involved by PNI correlates with prognosis in prostatic adenocarcinoma, 17 oral squamous cell carcinoma, 3 and cutaneous squamous cell carcinoma. 21 In this study, we observed that involvement of nerve >0.8 mm by PNI was associated with a significantly higher frequency of positive resection margin. However, we did not observe any significant correlation of the size of the nerve involved by PNI with either OS or DFS using the 25th, 50th, or 75th percentile of the involved nerve sizes as cutoff for survival analysis in our study patient population. In contrast to the previous study, which showed that extratumoral PNI is associated with the development of peritoneal metastasis after surgery, 24 we did not observe any significant difference in any of the examined clinicopathologic parameters and survival between the group with intratumoral PNI and those with extratumoral PNI or between the group with intrapancreatic PNI only and the group with extrapancreatic PNI. This difference may be partly because of the selection of patients, who received neoadjuvant therapy before PD in our study population.
In summary, our data showed that the presence of PNI and intraneural invasion correlated with a significantly shorter DFS and OS in patients with PDAC who received neoadjuvant therapy. The presence of PNI was an independent prognostic factor for patients with PDAC who underwent PD after neoadjuvant chemoradiation. Our results suggest that PNI and intraneural invasion play an important role in the progression of PDAC and in predicting the clinical outcome in this group of patients.
